Copernicus Capital Management as of Sept. 30, 2020
Portfolio Holdings for Copernicus Capital Management
Copernicus Capital Management holds 18 positions in its portfolio as reported in the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Abbvie (ABBV) | 12.4 | $13M | 148k | 87.59 | |
| Bristol Myers Squibb (BMY) | 12.3 | $13M | 213k | 60.29 | |
| BioMarin Pharmaceutical (BMRN) | 12.0 | $13M | 165k | 76.08 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 11.7 | $12M | 45k | 272.11 | |
| Arena Pharmaceuticals Call | 6.1 | $6.4M | 86k | 74.79 | |
| Iqvia Holdings (IQV) | 5.9 | $6.2M | 39k | 157.64 | |
| Fate Therapeutics (FATE) | 5.8 | $6.1M | 153k | 39.97 | |
| Myokardia | 5.5 | $5.8M | 42k | 136.32 | |
| Gw Pharmaceuticals Ads | 4.9 | $5.1M | 53k | 97.36 | |
| Teladoc (TDOC) | 4.5 | $4.7M | 22k | 219.26 | |
| Translate Bio | 3.0 | $3.1M | 228k | 13.61 | |
| Arcus Biosciences Incorporated (RCUS) | 2.8 | $2.9M | 172k | 17.14 | |
| Revolution Medicines (RVMD) | 2.7 | $2.8M | 81k | 34.80 | |
| Neurocrine Biosciences (NBIX) | 2.6 | $2.7M | 28k | 96.14 | |
| Tg Therapeutics (TGTX) | 2.4 | $2.5M | 95k | 26.76 | |
| Cymabay Therapeutics | 1.9 | $2.0M | 278k | 7.24 | |
| Accolade (ACCD) | 1.9 | $1.9M | 50k | 38.88 | |
| Eiger Biopharmaceuticals | 1.8 | $1.9M | 238k | 8.14 |
